News
China’s 3SBio Soars on Granting Pfizer New Cancer Drug Rights in USD6 Billion Deal
3SBio will grant Pfizer exclusive global rights, not including China, to develop, manufacture and commercialize SSGJ-707, a bispecific antibody targeting PD-1 and VEGF for cancer treatment, according to the agreement announced yesterday. The deal also includes an option for Pfizer to acquire commercialization rights in China.
The deal comes three months after Pfizer inked a PD-1/VEGF partnership with Summit Therapeutics, leading BMO Capital Markets ...
Pfizer has entered into an exclusive global licensing agreement with 3SBio to develop, manufacture, and commercialize SSGJ-707, a bispecific antibody targeting PD-1 and VEGF pathways. The therapy ...
No patent infringement found in exports of individual conjugate bulk substances and research-use finished products of PCV13 ...
The largest Chinese licensing deal behind Pfizer’s is Novartis’ partnership with Shanghai Argo Biopharma, worth potentially ...
Pfizer's reported interest in acquiring sickle cell disease specialist Global Blood Therapeutics ... If those results are positive the partners have said they could file for approval in the ...
including obesity by advancing internal programs such as our GIPR antagonist and pursuing external opportunities that could include partnerships or acquisitions. While Chris Boshoff, Pfizer's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback